Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China

Sponsor
International Vaccine Institute (Other)
Overall Status
Completed
CT.gov ID
NCT00131833
Collaborator
Centers for Disease Control and Prevention (U.S. Fed), Hechi City Center for Disease Centrol (Other), Wellcome Trust (Other), University of Western Ontario, Canada (Other)
96,468
1
61
1581.2

Study Details

Study Description

Brief Summary

This study is part of International Vaccine Institute (IVI)'s typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries. The purpose of this study is to determine the effectiveness of the Vi vaccine following a mass typhoid immunization campaign in an endemic area in Hechi City in the Guangxhi province of China. The cost-effectiveness and safety of Vi vaccination will also be evaluated.

Condition or Disease Intervention/Treatment Phase
  • Biological: Typhoid Vi vaccine
  • Biological: Meningococcal A (control)
Phase 4

Detailed Description

Typhoid fever is a major cause of morbidity worldwide. The disease predominantly affects school-aged children, is more prevalent in urban areas, may last for several weeks and can lead to serious complications. Management of this disease is further complicated by the emergence of multi-drug resistant strains. Vaccination of high risk populations is considered the most promising strategy for the control of typhoid fever. The Vi polysaccharide vaccine has been targeted for accelerated introduction into public health programs due to the following reasons: it has been shown to have consistent efficacy results even in areas of high typhoid incidence, is given as a single dose, lacks patent protection and requires less strict cold chain requirements.

This project attempts to evaluate a new vaccination strategy for residents of endemic areas. A cluster-randomized trial involving the Vi polysaccharide vaccine and an active control (meningococcal A vaccine) was designed to determine the effectiveness and the feasibility of providing Vi vaccine under actual programmatic conditions in 2 populous townships of Hechi City. The vaccines used in this study are locally produced and licensed in China. A 1 year pilot phase will precede the actual Vi-demonstration project. Surveillance for typhoid fever cases will continue after the mass immunization campaign. A passive surveillance system to evaluate adverse events following immunization will be implemented. Socio-economic studies will be conducted in parallel to the effectiveness evaluation. The knowledge, attitudes, beliefs and practices among parents and health care providers regarding typhoid illness, treatment and prevention will be assessed. Logistic, feasibility and vaccine costs will also be determined.

Secondary objectives of this trial are:
  • To estimate the logistic feasibility of a mass typhoid immunization campaign

  • To assess the knowledge, attitudes, beliefs and practices among parents and health care providers regarding typhoid illness, treatment and prevention

  • To study typhoid fever risk factors in the population

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
Double
Primary Purpose:
Prevention
Official Title:
Typhoid Vi Vaccine Effectiveness in a Population Older Than 5 Years of Age Living in an Endemic Area in Hechi, Guangxi, P.R. China: A Group-Randomized Controlled Demonstration Project
Study Start Date :
Oct 1, 2001
Actual Primary Completion Date :
Nov 1, 2006
Actual Study Completion Date :
Nov 1, 2006

Outcome Measures

Primary Outcome Measures

  1. vaccine effectiveness []

  2. cost effectiveness of typhoid Vi immunization []

  3. adverse events []

Secondary Outcome Measures

  1. logistic feasibility of mass typhoid immunization []

  2. anti-Vi antibody response []

  3. knowledge, attitudes, beliefs and practices of parents and health care providers on typhoid fever prevention and treatment []

  4. Typhoid risk factors []

Eligibility Criteria

Criteria

Ages Eligible for Study:
5 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Registered in the project census
Exclusion Criteria:
  • Pregnant

  • Lactating

  • Fever > 37.5 degrees Celsius, axillary

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hechi City Center for Disease Control Hechi City Guangxi China 54700

Sponsors and Collaborators

  • International Vaccine Institute
  • Centers for Disease Control and Prevention
  • Hechi City Center for Disease Centrol
  • Wellcome Trust
  • University of Western Ontario, Canada

Investigators

  • Principal Investigator: Dong Baiqing, MD, Guangxi Center for Disease Control and Prevention

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00131833
Other Study ID Numbers:
  • T3
First Posted:
Aug 19, 2005
Last Update Posted:
Mar 13, 2008
Last Verified:
Mar 1, 2008
Keywords provided by , ,
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 13, 2008